|
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment Clinical research trials and The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment. The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): Merck ,
Synopsis: The purpose of this study is to see if it is safe and effective to give indinavir plus ritonavir plus 2 NRTIs to HIV-infected patients who need early intervention treatment.
Details: Patients receive indinavir bid plus ritonavir bid, plus 2 NRTIs bid (2 new NRTIs or 1 new NRTI and 1 NRTI without evidence of resistance). CD4 cell counts and plasma viral RNA are measured every 4 weeks for the duration of the study. Physical examination and laboratory tests of blood and urine are performed every 4 weeks for the duration of the study. Chest x-ray and 12-lead ECG are done prestudy.
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive. - Are 18 years of age or older. - Have a CD4 cell count of at least 50 cells/mm3. - Have a viral load (level of HIV in the blood) of at least 400 copies/ml but no more than 20,000 copies/ml. - Have had an initial response to protease inhibitor therapy with a viral load of less than 400 copies/ml in two consecutive tests at least 1 week apart. - Have been on anti-HIV (antiretroviral) treatment including indinavir or nelfinavir for at least 16 weeks. - Have had virologic failure (two consecutive viral loads that were greater than or equal to 400 copies/ml and less than or equal to 20,000 copies/ml at least 1 week apart) that is not due to another infection, vaccination, or a temporary stop in treatment. - Are naive to at least one of the selected NRTIs.
Total Enrollment: 100
Location and Contact Information:
Dr Ronald Nahass
Somerville, New Jersey, 08876
United States
Mount Sinai Med Ctr
New York City, New York, 100296574
United States
Thomas Street Clinic
Houston, Texas, 77009
United States
Gramercy Park Physicians LLP
New York City, New York, 10003
United States
Bellevue Hosp Ctr
New York City, New York, 10016
United States
SUNY at Stony Brook / Div of Infectious Disease
Stony Brook, New York, 117948153
United States
Univ of Texas Health Sciences Ctr
San Antonio, Texas, 782847838
United States
Tower Infectious Diseases / Med Associates Inc
Los Angeles, California, 90048
United States
Northwestern Univ / Infect Dis Div / Pasavant Pav 828
Chicago, Illinois, 60611
United States
Univ of Kansas School of Medicine
Wichita, Kansas, 67214
United States
Wake Forest Univ School of Medicine
Winston Salem, North Carolina, 27157
United States
The CORE Ctr
Chicago, Illinois, 60612
United States
Univ of Texas Med Branch / Div of Infectious Dis
Galveston, Texas, 775550835
United States
IDC Research Initiative
Altamonte Springs, Florida, 32701
United States
HIV Institute / Davies Med Ctr
San Francisco, California, 94114
United States
Fanno Creek Clinic
Portland, Oregon, 97219
United States
New England Med Ctr
Boston, Massachusetts, 02111
United States
UCSD Med Ctr - Owen Clinic
San Diego, California, 921038681
United States
Avalar Medical Group
Tarzana, California, 91356
United States
Cooper Hospital Early Intervention Program
Camden, New Jersey, 08103
United States
Bisher Akil
Los Angeles, California, 90046
United States
Mercer University School of Medicine
Macon, Georgia, 31201
United States
Anderson Clinical Research
Pittsburgh, Pennsylvania, 15213
United States
Pacific Oaks Research
Beverly Hills, California, 90211
United States
St Luke Roosevelt Hosp
New York City, New York, 10011
United States
Oklahoma Univ Health Science Ctr
Oklahoma City, Oklahoma, 73104
United States
Mt Vernon Hosp
Mt. Vernon, New York, 10550
United States
Ocean View Internal Medicine
Long Beach, California, 90803
United States
St Vincents Hosp / Clinical Research Program
New York City, New York, 10011
United States
University of Louisville / ID Division
Louisville, Kentucky, 40202
United States
Tulane Univ School of Medicine
New Orleans, Louisiana, 70112
United States
Benjamin Young
Denver, Colorado, 80220
United States
Chicago Ctr for Clinical Research
Chicago, Illinois, 60610
United States
Hillsborough County Health Dept
Tampa, Florida, 33602
United States
Institute of Human Virology
Baltimore, Maryland, 21201
United States
University of Connecticut Health Center
Farmington, Connecticut, 06030
United States
Harbor - UCLA Med Ctr
Torrance, California, 90502
United States
Thomas Coffman MD
Boise, Idaho, 83712
United States
Bronx Veterans Affairs Med Ctr
Bronx, New York, 10468
United States
San Francisco Veterans Adm Med Cntr
San Francisco, California, 94121
United States
Additional Information:
Study ID Numbers: 246V; CRX481,107-00
Study Start Date:
Record last reviewed: July 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005118
Other Hiv Infections Studies:
1. A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children with Immunodeficiency Syndromes
2. A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)
3. A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
4. The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
5. The Effect of Teaching HIV-Infected Patients about HIV and Treatment
Related Studies:
Other HIV Infections Clinical Trials
Other Oklahoma Clinical Trials
Other Oklahoma City Clinical Trials
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
|
|
|
|
|
|
|
|